Your browser is no longer supported. Please, upgrade your browser.
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.43 Insider Own1.76% Shs Outstand10.59M Perf Week117.89%
Market Cap109.61M Forward P/E- EPS next Y-2.58 Insider Trans-0.41% Shs Float- Perf Month95.28%
Income-75.30M PEG- EPS next Q-0.83 Inst Own60.00% Short Float- Perf Quarter155.56%
Sales- P/S- EPS this Y-10.00% Inst Trans-16.65% Short Ratio0.95 Perf Half Y102.94%
Book/sh3.33 P/B3.11 EPS next Y21.10% ROA-86.50% Target Price9.00 Perf Year88.52%
Cash/sh8.30 P/C1.25 EPS next 5Y- ROE-101.80% 52W Range2.70 - 12.40 Perf YTD117.89%
Dividend- P/FCF- EPS past 5Y-16.40% ROI- 52W High-16.53% Beta1.34
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low283.33% ATR0.86
Employees52 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)79.30 Volatility14.36% 8.26%
OptionableYes Debt/Eq0.00 EPS Q/Q33.70% Profit Margin- Rel Volume0.49 Prev Close10.45
ShortableYes LT Debt/Eq0.00 EarningsAug 03 Payout- Avg Volume1.20M Price10.35
Recom2.20 SMA2065.20% SMA5092.90% SMA200112.76% Volume592,424 Change-0.96%
Sep-19-17Initiated Oppenheimer Outperform $18
Sep-15-17Reiterated Leerink Partners Mkt Perform $7 → $9
Nov-17-16Initiated H.C. Wainwright Buy $12
Jun-06-16Reiterated Wedbush Outperform $29 → $27
Jun-06-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-06-16Downgrade Jefferies Buy → Hold
May-24-16Reiterated Wedbush Outperform $41 → $29
May-09-16Reiterated Wedbush Outperform $45 → $41
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $32
Feb-17-16Resumed Jefferies Buy
Jan-13-16Upgrade Citigroup Neutral → Buy
Nov-23-15Initiated Citigroup Neutral
Oct-19-15Initiated Barclays Overweight $50
Sep-17-15Downgrade Piper Jaffray Overweight → Neutral $50 → $45
Jun-01-15Reiterated Wedbush Outperform $34 → $45
Jun-01-15Downgrade Brean Capital Buy → Hold
May-29-15Initiated Citigroup Buy $45
May-08-15Reiterated Leerink Partners Outperform $27 → $35
May-08-15Reiterated Brean Capital Buy $27 → $34
Jul-08-14Resumed Brean Capital Buy $27
Sep-19-17 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
01:31PM  A Peek Into The Future For Mirati Therapeutics Benzinga
Sep-18-17 08:45AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
03:00AM  Mirati Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-15-17 12:07PM  Is It Too Late To Buy Mirati Therapeutics Inc (MRTX)? Simply Wall St. +135.79%
10:42AM  Mirati Therapeutics Sitravatinib Data, Explained Benzinga
09:24AM  Mirati Skyrockets On Positive Data - Biotech Movers TheStreet.com
08:27AM  Mirati Therapeutics' stock soars on heavy volume after positive cancer treatment trial results MarketWatch
Sep-14-17 04:30PM  Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer PR Newswire
Sep-06-17 02:00PM  Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer PR Newswire
Aug-30-17 04:15PM  Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference PR Newswire
Aug-21-17 08:15AM  Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher Zacks
Aug-03-17 07:09PM  Mirati reports 2Q loss Associated Press
04:05PM  Mirati Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire
Jul-18-17 08:30AM  Mirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher Zacks
Jul-05-17 04:15PM  Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York PR Newswire
Jun-27-17 04:05PM  Mirati Therapeutics Announces Appointment Of Neil Reisman To The Board Of Directors PR Newswire -7.41%
May-31-17 04:15PM  Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference PR Newswire -9.68%
May-04-17 06:38PM  Mirati reports 1Q loss Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
Mar-27-17 04:05PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Mar-15-17 01:04PM  MIRATI THERAPEUTICS, INC. Financials +6.67%
Mar-09-17 06:46PM  Mirati reports 4Q loss Associated Press
04:22PM  MIRATI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:05PM  Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016 PR Newswire
Feb-13-17 04:05PM  Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference PR Newswire
Feb-01-17 04:07PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
12:21PM  5 Stocks Insiders Love Right Now TheStreet.com
12:21PM  5 Stocks Insiders Love Right Now
Jan-22-17 10:25AM  Insider Buying Slows as Trump Inauguration Takes Center Stage: Kindred Biosciences, Mirati Therapeutics, City Office REIT and More
Jan-17-17 10:50AM  Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock TheStreet.com
10:50AM  Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock
Jan-09-17 03:57PM  Mirati Therapeutics Sets $65M Public Offering Investopedia
03:57PM  Mirati Therapeutics Sets $65M Public Offering at Investopedia
Jan-06-17 05:12PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jan-05-17 04:02PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events +7.27%
04:01PM  Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs PR Newswire
04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Dec-15-16 09:11PM  How CardConnect Corp (CCN) Stacks Up Against Its Peers at Insider Monkey
Dec-09-16 10:52AM  How Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry +5.36%
Dec-07-16 05:25AM  Is Mirati Therapeutics, Inc. (MRTX) Going to Burn These Hedge Funds? at Insider Monkey
Dec-01-16 08:42AM  Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-17-16 07:23AM  Coverage initiated on Mirati Therapeutics by H.C. Wainwright +5.26%
Nov-03-16 07:01PM  Mirati reports 3Q loss -5.94%
04:17PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:10PM  Mirati Therapeutics Reports Financial Results And Provides Business Update For The Third Quarter 2016 PR Newswire
Oct-04-16 07:30AM  Mirati Therapeutics Appoints Chris LeMasters To Role Of Executive Vice President And Chief Business Officer PR Newswire
Sep-29-16 04:07PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
07:30AM  Mirati Therapeutics Announces Appointment Of Dr. Bruce L.A. Carter To Board Of Directors PR Newswire
Sep-22-16 01:10PM  5 Stocks Under $10 That Could Make You a Lot of Money +17.67%
Sep-20-16 12:15PM  Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
Aug-12-16 07:22AM  7 Stocks Under $10 Making Big Up Moves
Aug-04-16 06:17PM  Mirati reports 2Q loss
04:18PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Mirati Therapeutics Reports Financial Results And Provides Business Update For The Second Quarter 2016 PR Newswire
Jul-21-16 04:04PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jul-18-16 11:05AM  10 Battered Biotech Stocks That Hit 52-Week Lows Friday at Insider Monkey
Jul-11-16 03:46PM  Hedge Funds Favorite Stocks That Have RSIs Under 30 at Insider Monkey
Jun-22-16 04:02PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
04:01PM  Mirati Therapeutics Announces Change In Executive Leadership PR Newswire
Jun-16-16 07:12PM  Insider Buys of More Than $aaa,aaa: Mirati Therapeutics
04:03PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
Jun-15-16 08:08AM  J M Smucker Co (SJM) Registers Noteworthy Cluster of Insider Selling, Plus Four Other Companies with Notable Insider Trading Activity at Insider Monkey
Jun-12-16 10:20AM  7 Biopharma Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Jun-10-16 09:33AM  These 5 Stocks Are Poised for Breakouts -15.90%
Jun-07-16 04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St. -9.31%
Jun-06-16 05:23PM  Why Sturm Ruger, Mirati Therapeutics, and Barracuda Networks Slumped Today at Motley Fool -44.41%
04:04PM  The 52-Week Low Club for Monday at 24/7 Wall St.
01:57PM  Why Tyson Foods, Fitbit, and Three Other Stocks Are Down As Major Indices Are in Green at Insider Monkey
12:16PM  Why Mirati Therapeutics, Inc.'s Shares Are Being Obliterated Today at Motley Fool
11:40AM  The 5 Biggest Biotech and Pharma Losers From ASCO at 24/7 Wall St.
08:32AM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-05-16 09:00AM  Mirati Therapeutics Provides Progress Update On Current Clinical Trials PR Newswire
Jun-02-16 01:01PM  Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 +5.24%
Jun-01-16 08:00AM  Mirati Therapeutics To Present At The Jefferies 2016 Healthcare Conference PR Newswire
May-23-16 04:04PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +5.38%
May-19-16 08:00AM  Mirati Therapeutics To Present Abstracts On Pipeline Programs At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-11-16 03:24PM  5 Stocks Insiders Love Right Now at TheStreet
May-05-16 07:34PM  Mirati reports 1Q loss
04:36PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:15PM  Mirati Therapeutics Reports Financial Results And Business Update For The First Quarter 2016 PR Newswire
Apr-13-16 04:05PM  QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer PR Newswire
Mar-30-16 02:52PM  5 Stocks Insiders Love Right Now at TheStreet
Mar-24-16 08:38AM  Mirati Therapeutics To Present Preclinical Data At 2016 American Association For Cancer Research Annual Meeting at noodls
08:30AM  Mirati Therapeutics To Present Preclinical Data At 2016 American Association For Cancer Research Annual Meeting PR Newswire
Mar-23-16 08:20PM  CFO Moves: Toscana Energy Income, Francesca's Holdings, Mirati Therapeutics at The Wall Street Journal -5.63%
04:08PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:58AM  Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer at noodls
08:30AM  Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer PR Newswire
Mar-09-16 05:03PM  Mirati reports 4Q loss
04:23PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:15PM  Mirati Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update PR Newswire
Mar-08-16 08:00AM  Mirati Therapeutics To Present At The Barclays Global Healthcare Conference PR Newswire -8.86%
Feb-17-16 02:41PM  Street Talk: TSN, DVN & more +7.23%
Jan-26-16 04:12PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-08-16 08:15AM  Mirati Therapeutics Appoints Marcy Graham Vice President, Investor Relations and Corporate Communications PR Newswire
Dec-21-15 08:16AM  Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial PR Newswire
08:16AM  Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC) PR Newswire
08:15AM  Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC) PR Newswire
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Christensen JamieSVP, Chief Science OfficerSep 15Sale12.007709,2402,670Sep 18 07:48 PM
Braslyn Ltd.10% OwnerJan 26Buy5.4548,169262,3282,880,702Jan 30 05:00 PM
Braslyn Ltd.10% OwnerJan 25Buy5.4230,600165,8522,832,533Jan 25 05:00 PM
Braslyn Ltd.10% OwnerJan 24Buy5.3227,682147,2682,801,933Jan 25 05:00 PM
Braslyn Ltd.10% OwnerJan 23Buy5.2719,251101,4532,774,251Jan 25 05:00 PM
Braslyn Ltd.10% OwnerJan 20Buy5.4223,873129,3922,755,000Jan 20 05:00 PM
Braslyn Ltd.10% OwnerJan 19Buy5.4821,085115,5462,731,127Jan 20 05:00 PM
Braslyn Ltd.10% OwnerJan 18Buy5.5016,20089,1002,710,042Jan 20 05:00 PM
Braslyn Ltd.10% OwnerJan 17Buy5.5017,80097,9002,693,842Jan 17 05:00 PM
Braslyn Ltd.10% OwnerJan 13Buy5.4952,311287,1872,676,042Jan 17 05:00 PM
Braslyn Ltd.10% OwnerJan 12Buy5.5049,776273,7682,623,731Jan 17 05:00 PM
Braslyn Ltd.10% OwnerJan 06Buy5.60581,8703,258,4722,573,955Jan 10 05:00 PM
Boxer Capital, LLC10% OwnerJan 06Buy5.60286,1631,602,5131,037,994Jan 10 05:00 PM